title: Proof of principle for crizotinib in anaplastic lymphoma kinase-positive malignancies was achieved in ALK-positive nonclinical models.
authors.affiliation: Pfizer Global Research and Development, Precision Medicine, La Jolla, San Diego, CA 92121, USA. james.christensen@pfizer.com
authors.forename: James G
authors.initials: JG
authors.lastname: Christensen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D005260:Female; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000473:pathology*; D010880:Piperidines / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011505:Protein-Tyrosine Kinases; D019859:Proto-Oncogene Proteins c-met